2. Academic Validation
  3. Recent advances of antibody drug conjugates for clinical applications

Recent advances of antibody drug conjugates for clinical applications

  • Acta Pharm Sin B. 2020 Sep;10(9):1589-1600. doi: 10.1016/j.apsb.2020.04.012.
Pengxuan Zhao 1 2,  Yuebao Zhang 1,  Wenqing Li 1,  Christopher Jeanty 1 3,  Guangya Xiang 2,  Yizhou Dong 1 4 5 6 7 8
Affiliations

Affiliations

  • 1 Division of Pharmaceutics & Pharmacology, College of Pharmacy, the Ohio State University, Columbus, OH 43210, USA.
  • 2 School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • 3 Neuroscience Program, College of Medicine & College of Arts and Sciences, the Ohio State University, Columbus, OH 43210, USA.
  • 4 Department of Biomedical Engineering, the Ohio State University, Columbus, OH 43210, USA.
  • 5 The Center for Clinical and Translational Science, the Ohio State University, Columbus, OH 43210, USA.
  • 6 The Comprehensive Cancer Center, the Ohio State University, Columbus, OH 43210, USA.
  • 7 Dorothy M. Davis Heart & Lung Research Institute, the Ohio State University, Columbus, OH 43210, USA.
  • 8 Department of Radiation Oncology, the Ohio State University, Columbus, OH 43210, USA.
PMID: 33088681 DOI: 10.1016/j.apsb.2020.04.012
Abstract

Antibody drug conjugates (ADCs) normally compose of a humanized antibody and small molecular drug via a chemical linker. After decades of preclinical and clinical studies, a series of ADCs have been widely used for treating specific tumor types in the clinic such as brentuximab vedotin (Adcetris®) for relapsed Hodgkin's lymphoma and systemic anaplastic large cell lymphoma, gemtuzumab ozogamicin (Mylotarg®) for acute myeloid leukemia, ado-trastuzumab emtansine (Kadcyla®) for HER2-positive metastatic breast Cancer, inotuzumab ozogamicin (Besponsa®) and most recently polatuzumab vedotin-piiq (Polivy®) for B cell malignancies. More than eighty ADCs have been investigated in different clinical stages from approximately six hundred clinical trials to date. This review summarizes the key elements of ADCs and highlights recent advances of ADCs, as well as important lessons learned from clinical data, and future directions.

Keywords

Antibody; Antibody drug conjugates; Clinical application; Cytotoxic agents; Linker.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z